Redirecting traffic using the XPO1 police-Reference-Cited by-同舟云学术

Redirecting traffic using the XPO1 police

Published:2013-10-24 Issue:17 Volume:122 Page:2926-2928
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Abraham Sheela A.¹,Holyoake Tessa L.¹

Affiliation:

1. UNIVERSITY OF GLASGOW

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/17/2926/1369762/2926.pdf

Reference8 articles.

1. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.;Walker;Blood,2013

2. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications [published online ahead of print April 16, 2013].;Tai;Leukemia

3. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.;Etchin;Br J Haematol,2013

4. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.;Lapalombella;Blood,2012

5. Nuclear export of proteins and drug resistance in cancer.;Turner;Biochem Pharmacol,2012

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selinexor (Xpovio), An XPO1 Inhibitor and A New Class of Therapeutics for Treating Multiple Myeloma;Current Drug Synthesis;2022-09-22

2. Selinexor and the Selective Inhibition of Nuclear Export: A New Perspective on the Treatment of Sarcomas and Other Solid and Non-Solid Tumors;Pharmaceutics;2021-09-20

3. Novel Targeted Treatment Approaches in Pancreatic Cancer;Textbook of Gastrointestinal Oncology;2019

4. XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB;Molecular Cancer Therapeutics;2018-12

5. Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer;Breast Cancer Research;2017-08-15